For Investors

Press Releases

Lifeward Announces Appointment of Joseph E. Turk as Incoming Chairman of its Board of Directors

07/02/24

Jeff Dykan, who led Lifeward as Chairman of its Board through the past 15 years, has announced his intent to retire at the end of his current term MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (Nasdaq: LFWD) (“Lifeward” or the

Read More
Read More

Lifeward Unveils Newest Addition to Its AlterG Anti-Gravity Product Line – Introducing AlterG NEO

06/26/24

The AlterG NEO combines updated user-friendly design with trusted Anti-Gravity technology for precise and consistent unweighting in physical rehabilitation and athletic training Updated features and a cost-effective price point make the core AlterG technology accessible for a broader range of

Read More
Read More

Lifeward to Present at Sidoti Virtual Investor Conference on June 12

06/04/24

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 04, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the

Read More
Read More

Lifeward Reports First Quarter 2024 Financial Results

05/15/24

Q1’24 revenue of $5.3M is up 340% vs. Q1’23 and at the midpoint of Lifeward’s guidance range Newly established Medicare payment for ReWalk Personal Exoskeleton favorably impacts Q1’24 results Medicare Administrative Contractors (“MACs”) approve 14 claims since fee schedule established MARLBOROUGH,

Read More
Read More

Lifeward to Report First Quarter Financial Results on May 15, 2024

05/07/24

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit

Read More
Read More

Lifeward Announces the Appointment of Mike Swinford to its Board of Directors

04/19/24

Experienced healthcare and rehabilitation technology professional brings more than 30 years of experience in commercialization and new business development MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (Nasdaq: LFWD)

Read More
Read More

Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton

04/12/24

Finalized Medicare reimbursement pathway for personal exoskeletons expands access for all eligible Medicare beneficiaries MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel , April 12, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global

Read More
Read More

Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate

04/01/24

Collaboration with CMS on final payment rate focuses on commercial transaction values for the latest generation of ReWalk Exoskeleton CMS indicates that recently issued fee schedule which omitted exoskeletons can be updated after April 1 to include the final payment rate once it is established

Read More
Read More

VA STAND Act introduced in the United States Senate

03/22/24

Bicameral legislation seeks to codify annual examinations and assessments for assistive technologies, including Personal Exoskeletons, for Veterans with Spinal Cord Injury MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq:

Read More
Read More

Lifeward Announces Reverse Share Split

03/13/24

Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™),

Read More
Read More

ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy

03/08/24

Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy. Additional study demonstrates that the improvements in walking speed and distance

Read More
Read More

Lifeward announces the Centers for Medicare & Medicaid Services (“CMS”) is deferring its final decision on the payment rate for personal exoskeletons so that more recent claims information on the current, more advanced ReWalk Personal Exoskeleton may be considered

03/01/24

The decision was communicated through CMS’ bi-annual Healthcare Common Procedure Coding System (“HCPCS”) coding memorandum released yesterday; payment amount determination for ReWalk Personal Exoskeletons will continue to be on a case-by-case basis until such determination is finalized, likely

Read More
Read More
Displaying 1 - 12 of 286